The Micro-Immunotherapy Medicine 2LARTH® Reduces Inflammation and Symptoms of Rheumatoid Arthritis In Vivo

Figure 6

Mode of action of tested MIM. (a) Oral administered MIM can interact with cells of the innate and adaptive immune system present in the gut, reducing systemic inflammation and in turn, local inflammation of the synovial compartment. (b) RA is characterized by the presence of cytokines in the synovial compartment, fibroblasts assume an aggressive inflammatory phenotype, and chondrocytes enhance their catabolism promoting articular destruction. The tested MIM aimed at reducing levels of proinflammatory cytokines involved in pain and clinical signs of RA.

(a)

(b)